A5011739266- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Urticaria and Related Conditions
- Contact Dermatitis and Allergies
- Autoimmune Bullous Skin Diseases
- IL-33, ST2, and ILC Pathways
- Transgenic Plants and Applications
- Psoriasis: Treatment and Pathogenesis
- Occupational exposure and asthma
- Adrenal Hormones and Disorders
- melanin and skin pigmentation
- Pharmaceutical studies and practices
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Nail Diseases and Treatments
- Complementary and Alternative Medicine Studies
- Drug-Induced Adverse Reactions
- Mast cells and histamine
- Pesticide Exposure and Toxicity
- Stress Responses and Cortisol
- Exercise and Physiological Responses
- Pharmacological Effects of Natural Compounds
- Skin Protection and Aging
- Acne and Rosacea Treatments and Effects
George Washington University
2019-2025
University of Connecticut
2025
Icahn School of Medicine at Mount Sinai
2014-2025
Cornell University
2025
Weill Cornell Medicine
2025
University of Puerto Rico, Medical Sciences Campus
2024
University of Southern California
2024
Texas Tech University
2024
Medical College of Wisconsin
2024
Indiana University – Purdue University Indianapolis
2024
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of and interleukin-13, type 2 cytokines that may be important drivers atopic or allergic diseases such as dermatitis.
Disability secondary to skin conditions is substantial worldwide. The Global Burden of Disease Study 2013 includes estimates global morbidity and mortality due diseases.To measure the burden diseases worldwide.For nonfatal estimates, data were found by literature search using PubMed Google Scholar in English Spanish for years 1980 through accessing administrative on hospital inpatient outpatient episodes. Data fatal based vital registration verbal autopsy data.Skin disease extracted from...
Dupilumab is an IL-4 receptor α mAb inhibiting signaling of and IL-13, key drivers type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases.This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, effects dupilumab on molecular/cellular lesional nonlesional skin phenotypes systemic 2 biomarkers moderate-to-severe atopic dermatitis (AD).Skin biopsy specimens blood were from 54 randomized 1:1 to weekly subcutaneous...
BackgroundThe patient burden and quality of life (QOL) impact atopic dermatitis (AD) in the United States population is not well established.ObjectiveTo elucidate AD US population.MethodsA cross-sectional, population-based study 602 adults was performed. Atopic determined using modified UK Diagnostic Criteria for AD. Its severity assessed self-reported global severity, Patient-Oriented Eczema Measure (POEM), Scoring (PO-SCORAD), PO-SCORAD-itch, sleep. Quality short-form (SF-)12 mental...
IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13.We sought to evaluate the efficacy safety of tralokinumab adults with moderate-to-severe AD.In this phase 2b study (NCT02347176), 204 were randomized 1:1:1:1 receive 45, 150, or 300 mg subcutaneous tralokinumab, placebo, every 2 weeks for 12 concomitant topical glucocorticoids. Coprimary end points change from baseline Eczema Area Severity...
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block receptors are limited.In a phase 3, double-blind trial, we randomly assigned patients dermatitis was unresponsive to topical agents or warranted systemic therapy (in 2:2:2:1 ratio) receive 200 mg 100 abrocitinib orally...
Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The objectives this study were to determine population United States, distribution disease severity, and its impact health-related quality life. Among 1,278 participating adults, (95% confidence interval) was 7.3% (5.9–8.8). Overall, 60.1% (56.1–64.1) participants classified as having mild, 28.9% (25.3–32.7) moderate, 11% severe (8.6–13.7) disease. Patients with those more had higher scores dermatology...
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. Objectives To evaluate the efficacy safety of baricitinib patients moderate-to-severe AD who had inadequate response to therapies. Methods In two independent, multicentre, double-blind, III monotherapy trials, BREEZE-AD1 BREEZE-AD2, adults were randomized : once-daily placebo, mg, or 4 mg for 16 weeks....
Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD).To investigate the efficacy safety abrocitinib adolescents adults AD identically designed trial.This 3, double-blinded, placebo-controlled, parallel-group randomized clinical included 12 years or older diagnosis for at least year inadequate response to topical medications given 4 weeks within 6 months....
Little is known on the current global prevalence of atopic dermatitis (AD) in pediatric population.To estimate real-world AD population and by disease severity.This international, cross-sectional, web-based survey children adolescents (6 months to <18 years old) was conducted following 18 countries: North America (Canada, United States), Latin (Argentina, Brazil, Columbia, Mexico), Europe (France, Germany, Italy, Spain, Kingdom), Middle East Eurasia (Israel, Saudi Arabia, Turkey, Arab...
BackgroundAtopic dermatitis is a chronic inflammatory skin disease characterized by pruritic lesions.ObjectiveWe sought to evaluate the safety and efficacy of multiple doses selective Janus kinase 1 inhibitor upadacitinib in patients with moderate severe atopic dermatitis.MethodsIn 16-week, double-blind, placebo-controlled, parallel-group, dose-ranging portion this 88-week trial 8 countries (ClinicalTrials.gov, NCT02925117; ongoing, not recruiting), adults inadequate control topical...
Abstract Background Atopic dermatitis ( AD ) is associated with multiple comorbid conditions, such as asthma and food allergy. We sought to determine the impact of eczema severity on development these disorders other non‐atopic comorbidities in . Methods used 2007 N ational S urvey C hildren's H ealth, a prospective questionnaire‐based study nationally representative sample 91,642 children aged 0–17 yr. Prevalence eczema, asthma, hay fever allergy, sleep impairment, healthcare utilization,...
Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, key driver of atopic dermatitis (AD).To evaluate the efficacy and safety tralokinumab in combination with topical corticosteroids (TCS) patients moderate-to-severe AD who were candidates for systemic therapy.This was double-blind, placebo plus TCS controlled phase III trial. Patients randomized 2 : 1 to subcutaneous 300 mg or every weeks (Q2W) as needed over 16 weeks. achieved an Investigator's...